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Introduction: Nanoparticles (NPs) are used extensively in drug delivery.
They are administered through various routes in the host, and their uptake
by the cellular environment has been observed in several pathways. After
uptake, NPs interact with cells to different extents, depending on their size,
shape, surface properties, ligands tagged to the surface and tumor archi-
tecture. Complete understanding of such cellular uptake mechanisms and
interactions of NPs is important for their effective use in drug delivery.
Areas covered: This article describes the various cellular pathways for NP
uptake, and the factors affecting NP uptake and interactions with cells.
Understanding these two important aspects will help in the future design of
NPs for effective and targeted drug delivery.
Expert opinion: Surface charge and ligands tagged on the surface of NPs play
a critical role in their uptake and interaction with cells; so surface modifica-
tions of NPs can offer increased drug delivery effectiveness, for example, the
coupling of ligands on the surface of NPs can increase cellular binding, and
NPs in biological fluids can be coated with proteins and as such can exert bio-
logical effects. All of the factors affecting NP uptake need to be investigated
thoroughly before interpreting any NP--cellular interactions.
Keywords: cellular interaction, cellular uptake, endocytosis, nanoparticles, targeting
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1. Introduction
Nanoparticles (NPs) are submicrometer-sized particles. Nanoparticles have found
widespread applications in the field of drug delivery [1]. The submicrometer size
of NPs offers some distinct advantages over microparticles as they are best suited
for intravenous delivery [2]. Nanoparticles are used to provide targeted delivery of
drugs, to improve bioavailability, to sustain drug gene effect in target tissue, to sol-
ubilize drugs for intravascular delivery, and to improve the stability of therapeutic
agents against enzymatic degradation [3]. Anatomic complexities of the blood--brain
barrier, the branching pathways of the pulmonary system and the tight epithelial
junctions of the skin have made it difficult for drugs to reach their therapeutic
targets. Nanoparticles can penetrate or overcome these barriers [4]. Nanoparticle-
mediated targeted delivery is used to direct NPs to specific tissues [5]. Nanoparticles
can be formulated for targeted delivery to the lymphatic system, brain, arterial walls,
lungs, liver and spleen or made for long-term systemic circulation [2]. The delivery
of drug to target tissue can be achieved in two ways: passive and active. Passive
targeting takes advantage of the permeability of tumor tissue. This is also known
as the enhanced permeation and retention effect (EPR) [6]. Cell-type specificity
introduced by actively targeted NPs through ligand conjugation has been shown
to enhance cellular uptake [7]. Depending on the nature of target sites, different
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ligands are used for targeted delivery. Uptake of NPs is pro-
portional to the expression level of receptors on targeted
site [8]. Higher concentration/density of ligands on the NP
surface leads to higher binding and uptake of NPs by the
target site [9].
The targeting capabilities of NPs are influenced by particle
size, surface charge, surface modification and hydrophobicity.
These parameters can affect cellular uptake, protein binding
and translocation from path of entry to the target site [10,11].
Among these, the size and size distributions of NPs are
important to determine their interaction with the cell mem-
brane and their penetration across the physiological barriers.
The size of NPs for crossing different biological barriers is
dependent on tissue, target site and circulation. For the cellu-
lar internalization of NPs, surface charge is important in
determining whether the NPs would cluster in blood flow
or would adhere to, or interact with oppositely charged
cells [12]. Nanoparticles administered by various routes come
into contact with cells. On contact, NPs entered into different
organelles depending on their size. Nanoparticles can enter
into cells and the cell nucleus, and can pass the blood--brain
barrier. Nanoparticles with different charges have been evalu-
ated for their effect on the host. Anionic NPs have been
reported as having no effect on blood--brain integrity, whereas
high concentrations of anionic and cationic NPs have been
found to be toxic for the blood--brain barriers. Nanoparticles
can also pass through loose vasculature of tumor endo-
thelium [7]. Nanoparticles’ interactions and uptake also
depend on the tumor architecture, targeting ligands and route
of administration [7,13,14].
Nanoparticles in the bloodstream also encounter plasma
proteins and immune cells. Uptake of NPs by immune cells
may occur by various pathways and can be enhanced by
adsorption of plasma proteins. This has been assumed to be
one of the ways of NP clearance from the site of application.
Nanoparticles in a biological medium are involved in drawing
several proteins and lipids, resulting in the formation of
a ‘corona’ in slow exchange with the environment [15,16].
Usually, biological identities of NPs undergo changes
inside the body. Despite the fantastic potential of NPs in
medicine, studies in relation to their cellular interactions are
unexplored [5]. Understanding such interactions is important
not only for engineering of NPs for cellular uptake, but also
for determining toxicity of NPs [5]. Knowledge of NPs’ iden-
tity and methods to assess them are required. Also, there is a
strong need to identify in vivo interactions of NPs with bio-
logical components. In this article, cellular pathways of NPs’
uptake and factors affecting their cellular uptake are reviewed.
The interactions of therapeutically used NPs with biological
components are also discussed.
2. Pathways for nanoparticle uptake
Nanoparticles are taken up by cellular systems through
endocytosis [17]. Endocytosis is a process by which cells absorb
molecules from outside by engulfing them with their cell
membrane [18]. This process is usually categorized into two
phenomena, namely phagocytosis and pinocytosis. Phagocy-
tosis is a cellular phenomenon that describes the process in
which phagocytes (specialized cells such as macrophages)
destroy foreign particles such as NPs in blood [19].
Transferrin-coated PLGA NPs are highly absorbed by brain
endothelial cells and enter cells by means of the caveolae path-
way [20]. Similar results have been reported for porous
NPs [21]. Gold NPs are usually internalized by a mechanism
involving pinocytosis [22]. Pinocytosis occurs by four different
mechanisms: macropinocytosis, caveolin-dependent endocy-
tosis, clathrin-dependent endocytosis and clathrin/caveolin-
independent endocytosis [23-25]. Macropinocytosis is involved
in the formation of lamellipodia-like plasma membrane
extensions. Interestingly, NPs > 200 nm can enter cells
through macropinosomes [26]. PEGylated-poly-L-lysine NPs
have been reported to undergo cellular uptake by macropino-
cytosis [26]. One of the important endocytic mechanisms is
receptor-mediated process. In this process, cellular membrane
binds NPs with receptors, wraps around these particles and
then pinches off to form vesicles [27]. It is assisted by specific
proteins, either clathrin or caveolae [27]. Clathrin coats
and spherical caveolae have diameters of 100 -- 200 and
50 -- 80 nm, respectively [28]. Clathrin-coated pits have the
ability to accumulate only NPs up to 100 nm [29]. Uptake
of NPs in clathrin-dependent endocytosis is limited to
receptor-bound ligands [26]. The internalization of NPs was
more efficient for particles smaller than the caveolae. Hence,
cellular uptake of 20 -- 40 nm NPs was 5 to 10 times more
than 100 nm NPs. It is the size of caveolae that restricts inter-
nalization of larger particles [30]. Viruses are usually budded at
optimal concentration of internalized particles [31,32]. Various
studies on targeted drug delivery into cells have shown
that the size of particles is indeed an important factor in
cellular uptake of NPs. Receptor-mediated endocytosis of
NPs is strongly size-dependent, with an optimal radius of
27 -- 30 nm for spherical particles [33,34]. The particles near
this optimal size are most efficiently taken by receptor-
mediated endocytosis [35]. Characteristics such as time,
threshold and optimal radii for particle endocytosis are
estimated as a function of the binding energy factor, bond
elasticity factor, and nonspecific attractive/repulsive factor at
the cell--particle interface [36].
Cellular internalization of NPs could happen through any
of these pathways depending on their size, shape and nature.
The charge on NPs undoubtedly determines the endocytic
pathways for cellular entry. Negatively charged NPs are endo-
cytosed by slower rate and are unable to utilize the clathrin-
mediated endocytosis pathway. On the other hand, positively
charged NPs are internalized rapidly by means of the clathrin-
mediated pathway [37]. Endocytosed NPs are usually confined
to endosomes. However, endosomal uptake of NPs can be
avoided if NPs are delivered by means of liposomes or
modifying their surface with cell-penetrating peptides [38].
Cellular interactions of therapeutically delivered nanoparticles
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Nanoparticle size and surface charge as well as the specific
ligands attached to the cell surface are crucial players deter-
mining NP uptake. Polycaprolactone/PEG/polycaprolactone
NPs containing doxorubicin are internalized in tumor cells
by endocytosis [39]. Nanoparticles with positively charged
groups at their surface such as polyethyleneimine or polyami-
doimine dendrimers can induce disruption of plasma mem-
brane. Such disruption in plasma membrane is responsible
for nanohole formation [40]. In addition to hole formation,
NPs have been found to precipitate at the cell surface. Some-
times, this kind of NP agglomeration at the cell surface results
in the disruption of cell function [41]. Smaller NPs interact
with cell membranes by forming holes, whereas larger NPs
wrap a lipid bilayer around themselves [42].
Modified glycol chitosan NPs have been investigated for
cellular uptake mechanism and intracellular fate [43]. Interest-
ingly, these NPs showed an enhanced distribution in the
whole cells compared with parent hydrophilic glycol chitosan
polymers [43]. In vitro experiments with endocytic inhibitors
have suggested that several distinct uptake pathways such as
clathrin-mediated endocytosis, caveolae-mediated endocytosis
and macropinocytosis are involved in the internalization of
glycol chitosan NPs. Some glycol chitosan NPs have also
been found trapped in the lysosomes on entry [43]. Similarly,
poly-L-lysine-PEG-DNA NPs are also taken by several cellular
pathways and are trapped in lysosomes on entry [44].
3. Factors affecting uptake and interaction of
NPs with cells
Numerous experimental studies have been conducted to
probe NP and cell interactions [45]. Nanoparticle uptake and
interaction depend on the composition, size, shape, surface
charge, passive targeting and surface ligands. Composition
of NPs also has been reported to affect their fate inside the
body. Nanoparticles are synthesized from different materials.
Biodegradable NPs are cleared rapidly from the body [46],
whereas non-biodegradable particles accumulate inside the
body for extended periods [47].
Nanoparticle uptake by cells is considered to be a
two-step process: binding of NPs to the cell surface, followed
by uptake of NPs by the specific endocytosis pathway. Nano-
particles have generally higher uptake compared with micro-
particles. The 100 nm particles have shown greater uptake
compared with 1 µm microparticles in the Caco-2 cell
line [48]. Particle size has a significant effect on cellular and tis-
sue uptake. In some cell lines, only the submicrometer size
particles are taken up efficiently [49]. Nanoparticle uptake by
cells is also affected by the shape of the NPs. Shape-
dependent influence on the cellular uptake of protein-
coated gold NPs has been studied using HeLa cells (ovarian
cancer cells), SNB19 cells (brain tumor cells) and STO cells
(fibroblast cells). It has been observed that spherical NPs
are taken up by cells more efficiently than rod-shaped
NPs [50,51]. Shape of NPs affects not only cellular uptake,
but also internalization. Spherical particles are internalized
at a higher rate than elliptical disks in endothelial cells
(Figure 1) [52]. Interestingly, polymer carriers of various size
(0.1 -- 10 µm) have been targeted to intercellular adhesion
molecules, and reported similar results [53]. Rod-like particles
have shown different endocytosis properties in HeLa cells
compared with spheres [54].
Conventional NPs are rapidly cleared from the body
by macrophages. To increase the persistence of NPs in the
bloodstream, the surface of NPs is modified by hydrophilic
polymers such as PEG, polyvinyl alcohol, and so on. Surface
modification of NPs has shown potential for medical appli-
cations such as drug targeting in terms of cellular binding,
internalization and intracellular transportation [55]. PEG is
frequently used for the surface modification of various poly-
meric NPs [56]. This is a hydrophilic, non-ionic polymer and
is known to have excellent biocompatibility. The primary
interest in preparing PEG-functionalized particles is to
improve the long-term systemic circulation of the NPs. In
particular, conjugating PEG chains to the surface of proteins
or particles has increased the duration in the bloodstream [57].
PEG coating on the surface of PLA has reduced the interac-
tion between the NPs and the enzymes of the digestive fluids.
On the other hand, this has increased uptake of encapsulated
drug in the bloodstream and lymphatic tissue [56]. PEG has
been used successfully for the modification of surface proper-
ties of polycaprolactone NPs for the lipophilic drug taxol [58].
The hydrophilic outer shell of mPEG and the hydrophobic
inner core of polycaprolactone-taxol have improved the effi-
ciency of loading into mPEG/polycaprolactone NPs. Another
good example of PEG-based surface modification of polyhex-
adecyl cyanoacrylate NPs has also been reported. This has
been documented with regard to reducing the natural blood
opsonization process of the particles. During this, recognition
of NPs by macrophages and the particles’ half-life in blood
have improved. PEGylated particles showed comparatively
higher uptake of drug by the spleen and the brain than
conventional non-PEGylated NPs [59].
Besides size of NPs, architecture of tissues and NPs also
affects uptake and interactions of NPs with cells. Angiogenic
blood vessels in tumor tissues have gaps as large as
600 -- 800 nm between adjacent endothelial cells. This loose
architecture induces passive targeting, which allows NPs
to permeate through these gaps and accumulate inside tumor
tissues [60]. Nanoparticles can be localized in tumors by passive
targeting [61]. Doxorubicin-loaded polycaprolactone/PEG/pol-
ycaprolactone NPs were passively targeted to the tumor tissue
by the passive targeting effect. Doxorubicin is released in tumor
tissue rather than normal tissue. Doxorubicin in NPs could
treat mice bearing subcutaneous C-26 tumors more effi-
ciently [39]. Polyethylene oxide-modified poly(b-aminoester)
NPs also showed considerable tumor targeting potential by
means of a passive targeting mechanism [62].
Passively targeted NPs suffer from the limitations of
specificity. This problem can be overcome by active targeting.
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Nanoparticles can be targeted to the particulate region of cap-
illary endothelium to concentrate the drug within a particular
region and allow it to diffuse from the carrier to the target tis-
sue. Active targeting is usually achieved by attaching NPs to
targeting ligand, thereby allowing preferential accumulation
of drug in tumor tissue, within individual cancer cells, intra-
cellular organelles or specific molecules. Ligands attached to
the surface of NPs also have a role in deciding their fate inside
the body. Nanoparticles with specific recognition ligands
bound to the surface have good potential for site-selective
uptake as well as improved specificity for drug targeting [63].
This strategy has been used to direct NPs to cell surface carbo-
hydrates, receptors and antigens [6]. Ligands attached to the
surface can include any molecule that selectively recognizes
and binds molecules on target cells [64]. Only those ligands
whose antigen or receptors are overexpressed on cancer
cells can be used. Antibodies, oligopeptides, carbohydrates,
glycolipids and folic acid are the most widely used ligands
for targeting different organs and tissues.
Monoclonal antibody-coated poly(lactic-co-glycolic) acid
NPs used in the co-culture of MCF-10A neoT and Caco-2
cells are localized solely to MCF-10A neoT cells. This has
documented cell-specific internalization of NPs [65]; but use
of monoclonal antibodies is associated with certain disadvan-
tages. Monoclonal antibodies show poor in vivo mobility and
reduced uptake owing to their larger sizes. Moreover, mono-
clonal antibodies raised from murine and chimeric mouse
for humans are immunogenic and as such produce harmful
side effects. In sharp contrast, peptides have low immunoge-
nicity; but peptides show increased diffusion rates in tissues
owing to their smaller size [66,67]. Hence, use of peptides is
considered to be a better alternative approach to monoclonal
antibodies. Receptors for peptides are highly expressed on a
variety of neoplastic and non-neoplastic cells [68]. Receptor-
targeting peptides undergo internalization by means of
receptor-mediated endocytosis. Attachment of a positively
charged tat peptide to the NPs’ surface has resulted in effi-
cient internalization of NPs through electrostatic inter-
actions. Such an attachment of NPs with tat peptide has
increased further the NPs’ clearance from the vascular com-
partment [69]. Functionalization of gold NPs with tat protein
has allowed penetration across the cell membrane and entry
into the nucleus [70]. Gastrin-releasing peptide receptors are
overexpressed in various human tumors such as glioblastoma,
small cell lung, gastric, pancreatic, prostrate, breast, cervical
and colon cancer [71-74]. Gold NPs conjugated with bombesin
peptide can penetrate cells that are overexpressing gastrin-
releasing peptide receptors [68]. Peptidomimetic NPs can pro-
vide stronger interaction with surface receptors on tumor
cells, resulting in higher uptake and reduced drug resistance.
Self-assembled NPs conjugated with peptidomimetic antigens
to dendritic cells have resulted in subsequent activation
of T cells. The activation of T cells has mediated adaptive
immune response [75].
Tumor cells express multiple receptors. These receptors
can be targeted for increasing the efficacy, selectivity and
Shape ChargeA. B.
C. Temperature
High temperature Low temperatur
Figure 1. A. Effect of different parameters on cellular uptake of NPs. Spherical particles are efficiently taken up by cells.
B. Positively charged particles are well taken up by cells. C. High temperature allows both cellular uptake and interaction,
whereas at low temperature only interaction of NPs takes place.
NPs: Nanoparticles.
Cellular interactions of therapeutically delivered nanoparticles
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specificity of anticancer drugs. Estrogen receptor-positive
MCF-7 breast cancer cells have been used to examine the effi-
ciency of 100 -- 300 nm tamoxifen-loaded polycaprolactone
NPs. The location of estrogen receptor on the periphery of
the nuclear membrane has increased the therapeutic benefit
of tamoxifen-loaded NPs [76]. Similarly, tamixifen gold NP
conjugates selectively targeted estrogen receptor-a in human
breast cancer cells with up to 2.7 times enhanced potency. It
has been found that plasma membrane-localized estrogen
receptor-a facilitates selective endocytotic transport of these
and other therapeutic NP conjugates [77].
Transferrin is another well-studied ligand for targeted
delivery to tumor cells. Transferrin receptors are also
expressed on the surface of tumor cells. Transferrin ligand
is actively taken up by transferrin receptors by means of
receptor-mediated endocytosis. Gold NPs conjugated to
transferrin ligand have been internalized into nasopharyn-
geal carcinoma cells. This has resulted in localization of
most of the NPs in the cytoplasm of cells [78]. Some applica-
tions require the binding of NPs to specific protein or poly-
saccharide ligands on the cell surface. Such binding is also
affected by particle size. An increase in particle size from
50 to 200 nm reduces the affinity of biotin--streptavidin
interactions; whereas higher concentration of ligands on
particle surfaces shows stronger binding with their
counterparts [9].
A small non-antigenic molecule folic acid can also be used
for targeted delivery [79]. Folic acid has some advantages over
transferrin or antibodies as a ligand for long-circulating car-
riers. This is due to a much smaller molecule, unlikely to
interact with opsonins, and is coupled easily to a PEG chain
without loss of receptor binding activity [14]. Folic acid is a
stable, inexpensive, non-immunogenic molecule. It has very
high affinity for its cell surface receptors. Folate receptors
are considered to be useful targets for tumor-specific drug
delivery. Folate receptors have been observed to be upregu-
lated in many human cancers, including ovary, brain, kidney,
breast and lung [80]. Further, folate density increases with the
increase in cancer stage [81]. Keeping these in view, folic acid
has been conjugated to NPs for targeting folate receptors on
tumor cells [8]. Uptake of folate-conjugated NPs has been
found to be proportional to folate expression level in tumor
cells [8]. Targeting tumors with folate-targeted nanocarriers
is now considered to be a popular approach [82]. Folic acid
conjugated to mesoporous silica NPs has shown five times
more internalization by cancer cells that are expressing folate
receptors at higher levels [83]. Similar results have been
reported for paclitaxel-loaded folate-conjugated PEG/
polycaprolactone micelles. PEG/polycaprolactone micelles
were endocytosed into MCF-7 cells through interactions
with overexpressed folate receptors [84]. Surface-modified
PEG-polycaprolactone particles with folate, on loading
with paclitaxel, have shown increased cytotoxicity [85]. Cell
uptake and tumor retention are significantly enhanced by
folate-coated gadolinium NPs. Thus, the benefit of folate
ligand coating is to facilitate tumor cell internalization and
retention of gadolinium NPs in the tumor tissue [86].
Doxorubicin-loaded folate-PEG-functionalized gold NPs
have been used for targeted delivery to folate receptor-
positive cells. The doxorubicin nanocarriers show higher cyto-
toxic effect on folate receptor-positive cells (KB cells) than
folate receptor-negative cells (A549 cells) [87]. Folate-PEG-
grafted gold NPs have been selectively taken by KB cells
that are expressing folate receptors [80]. Interestingly, folate-
targeted liposomes show rapid accumulation in IGROV-1
tumors [88]. Protoporphyrin-IX-loaded folic acid-conjugated
chitosan NPs are internalized by HT29 and Caco-2-cell lines
by means of receptor-mediated endocytosis [89]. For these
reasons, NPs with high affinity for folate receptors are now
in development.
Wheat-germ agglutinin-conjugated poly(lactic-co-glycolic)
acid NPs containing isopropyl myristate have shown a
stronger cell killing effect. This was owing to more effi-
cient cellular uptake by means of wheat-germ agglutinin
receptor-mediated endocytosis in A549 and H1299 cells [90].
Carbohydrates on the cell surface contribute a variety of
communications between the cell and its environment.
The 2-methacryloyoxyethyl phosphorylcholine NPs bearing
hydrazide groups on reaction with levulinoyl mannosamine-
treated HeLa cells have shown NP accumulation. This
indicates that hydrazide groups of the NPs have reacted with
ketone groups of carbohydrates on the surface of HeLa cells.
The NPs also recognized levulinoyl mannosamine-treated
HeLa cells because of the ketone-functionalized unnatural
carbohydrates on their surfaces [91]. Lectin carbohydrate is a
classical example of active drug targeting. Lectins are able to
detect changes on cell surface carbohydrates of tumor cells.
This interaction can be made use of by direct lectin targeting
or reverse lectin targeting of drug molecules. Unfortunately,
the drug delivery systems based on this strategy were found
to deliver the drug molecule to whole organs, and therefore
to be harmful to other tissues [92].
Charge on NPs can have an influence on uptake and
interaction with cells; whereas neutral functional groups
are excellent at preventing interactions of unwanted NPs
with cells. Most charged functional groups are responsible
for active NP interactions with cells [93]. Cho et al. have
recently examined the role of surface charge in internaliza-
tion of gold NPs [94]. Similarly, the uptake of iron oxide
NPs functionalized with differently charged carbohydrates
has been studied in human cervical carcinoma cell lines [95].
In particular, cationic and anionic NPs have been observed
to follow different internalization pathways to enter cells.
Internalization of negatively charged NPs was believed to
occur through nonspecific binding and clustering of
particles on cationic sites of the plasma membrane and
their subsequent endocytosis. Cationic particles are well
known to bind to negatively charged groups on the cell
surface (Figure 1) [96]. Interestingly, positive charge has an
enhancing effect on the uptake rate compared with neutral
Kumari & Yadav
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or negatively charge carriers [96]. Brain uptake rates of
anionic NPs have been reported to be superior to cationic
and neutral NPs [97]. Negatively charged NPs have dis-
played a less efficient rate of endocytosis. However, posi-
tively charged NPs are internalized rapidly by means of a
clathrin-mediated pathway. The slight changes in surface
functionalities of NPs bearing cationic surface groups can
lead to varying amounts of cellular internalization [98].
This has indicated that the effect of NPs’ surface properties
on their interaction with cells is far more complicated than
understood at present. Similarly, polyethyleneimine coating
on mesoporous silica NPs has enhanced cellular uptake of
siRNA and DNA constructs. Furthermore, positive charge
of polyethyleneimine-coated NPs has led to strong electro-
static interactions with negatively charged cell membrane [99].
Positively charged NPs depolarize the plasma membrane,
leading to membrane potential perturbations and increased
Ca2+ influx (Figure 2). This has inhibited the proliferation
of normal cells, whereas malignant cells remain unaf-
fected [5]. Different surface charges on NPs have resulted
in repulsion, adhesion, or penetration into lipid bilayers.
The binding between NPs and lipid bilayers is mainly dic-
tated by electrostatic interactions between functionalized
ligands of NPs and lipid bilayer head groups. On penetra-
tion of NPs into lipid membrane, the NPs associated with
membrane disruption. The level of penetration and mem-
brane disruption increased with increasing charge density
on NPs [100].
Charged NPs can also induce hemolysis, thrombogenicity
and activation of complement system. Hemolytic tendency
also increases with an increase in charged groups [101].
Hydrophilic surfaces of NPs also induce hemolysis [102];
whereas the addition of PEG to the NPs’ surface has been
shown to reduce hemolytic activity [103]. Nanoparticles
have also been reported to induce activation and platelet
aggregation. Decorating particle surfaces with PEG decreases
platelet aggregation and activation [104]. Nanoparticles’ sur-
face charge has also caused activation of complement system.
Charged particles have more actively invoked complement
system than neutral ones [105,106]. Another study recently
reported that complement system activation by positively
charged NPs was suppressed by phospholipid and BSA
loading in the NPs [107].
The biological activity and biokinetics of NPs depend
on different parameters, such as size, shape, chemistry,
crystallinity, surface properties (area, porosity, charge, sur-
face modifications, coating), agglomeration state, biopersis-
tence and dose. These parameters are likely to modify
biological responses, such as translocation across epithelia
to other organs, induction of oxidative stress, binding to
proteins and receptors, and localization in cellular organ-
elles as mitochondria. As NPs today are more often used
in different products, there is an increased risk of exposure
of workers, consumers and the general public. Exposure to
NPs could be through the use of consumer products,
emerging biomedical applications of NPs as drug-
delivery agents, biosensors, or imaging contrast agents
that involve deliberate, direct ingestion or injection of
NPs into the body. Nanoparticles are administered in sev-
eral ways, such as oral, intravenous, cutaneous, intraperito-
neal, and so on [108,109]. After administration into the
body, NPs interact with biological components such as
proteins and cells. Thereafter, they are distributed to dif-
ferent organs of the body. There is a growing body of lit-
erature that details various degrees of adverse biological
effects induced by NPs at cellular, subcellular and molecu-
lar scales [110-114]. At present, no standard protocol is avail-
able for nanotoxicity testing. However, the key elements
for toxicity screening strategy should include physicochem-
ical characterization of NPs, in vitro assays (cellular and
non-cellular) and in vivo studies. Further, it is important
that the toxicity testing design should be pragmatic and
mechanism-based to draw final conclusions about toxicity
of NPs.
4. Expert opinion
Cellular uptake and interaction of NPs are affected by the
size, shape, surface charge, tumor architecture and the
ligand tagged to the surface of the NPs. The composition
and surface properties of NPs play a crucial role in their
interaction with cells. Nanoparticles are synthesized using
different kinds of material. Biodegradable materials are
degraded but non-biodegradable materials are retained
inside the body for a longer time. Hence, non-biodegradable
particles will interact with cellular components for a longer
time. Most NPs are internalized through endocytosis and
remain trapped in endolysosomal vesicles. Nanoparticles
with neutral surface coatings resist the interaction with cells
and consequently display minimal internalization. Studies
have also reported the uptake of negatively charged NPs
into cells, despite their repulsion by negatively charged
membrane. Positively charged NPs, however, are most
effective in crossing cell-membrane barriers and localizing
in the cytosol by depolarizing the membrane to a greater
extent compared with other particles. Cellular uptake and
interactions of NPs can be modulated by changing the
surface properties and varying the nature of the ligands
attached to them. Nanoparticle interactions with cells
depend not only on slight structural changes in the
surface ligands but also on the spatial arrangement of
ligands on the NPs’ surface. For targeted delivery, ligands
are conjugated to the surface of NPs. Conjugation techni-
ques are standardized in order to maintain the activity and
specificity of ligands.
For drug delivery, cellular targeting of NPs is very
important. Nanoparticles generally end in endosomes or
lysosomes followed by degradation. Chemical properties
such as surface charge may also determine the fate of NPs in
cells. Surface modifications of NPs offer ways for cellular
Cellular interactions of therapeutically delivered nanoparticles
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binding, uptake and intracellular transport. Coupling of
ligands on the surface of NPs also increases cellular binding.
Nanoparticles in biological fluids can be coated with proteins
and as such can have biological effects. Therefore, more exten-
sive studies are needed to investigate binding affinities and
stoichiometries for different protein NP formulations. All
the factors affecting NP uptake need to be investigated thor-
oughly before interpreting any NP--cellular interactions.
This is just the beginning towards investigating NP--cell inter-
actions; more extensive studies are needed to reach the
final conclusion.
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